携带19号外显子缺失突变的晚期肺腺癌在接受酪氨酸激酶抑制剂治疗后转变为鳞状细胞癌。
Advanced lung adenocarcinoma with 19-del mutation transforms into squamous cell carcinoma after tyrosine kinase inhibitor treatment.
作者信息
Qi Ruo-Bing, Wu Zheng-Hao
机构信息
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China.
出版信息
World J Clin Cases. 2024 Nov 16;12(32):6543-6546. doi: 10.12998/wjcc.v12.i32.6543.
Abstract
In this editorial we comment on the article by Ji . We focus specifically on the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and the development of drug resistance to EGFR-TKIs.
摘要
在这篇社论中，我们对Ji的文章进行评论。我们特别关注表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗以及对EGFR-TKIs的耐药性发展。
相似文献
1
Advanced lung adenocarcinoma with 19-del mutation transforms into squamous cell carcinoma after tyrosine kinase inhibitor treatment.携带19号外显子缺失突变的晚期肺腺癌在接受酪氨酸激酶抑制剂治疗后转变为鳞状细胞癌。
World J Clin Cases. 2024 Nov 16;12(32):6543-6546. doi: 10.12998/wjcc.v12.i32.6543.
2
Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment: A Case report.表皮生长因子受体19号外显子缺失突变的晚期肺腺癌在表皮生长因子受体酪氨酸激酶抑制剂治疗后转化为鳞状细胞癌：一例报告
World J Clin Cases. 2024 Jul 16;12(20):4405-4411. doi: 10.12998/wjcc.v12.i20.4405.
3
Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced -Mutant Lung Adenocarcinoma.晚期 - 突变肺腺癌患者对第三代 EGFR-TKI 获得性耐药后的组织学转化。
Medicina (Kaunas). 2022 Jul 8;58(7):908. doi: 10.3390/medicina58070908.
4
Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: A case report and literature review.腺癌向鳞状细胞癌转化作为表皮生长因子受体酪氨酸激酶抑制剂耐药的一个来源：一例病例报告及文献综述
Front Oncol. 2022 Sep 8;12:942084. doi: 10.3389/fonc.2022.942084. eCollection 2022.
5
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.表皮生长因子受体（EGFR）酪氨酸激酶抑制剂治疗的肺腺癌细胞的定量酪氨酸磷酸化蛋白质组学揭示了治疗反应的潜在新型生物标志物。
Mol Cell Proteomics. 2017 May;16(5):891-910. doi: 10.1074/mcp.M117.067439. Epub 2017 Mar 22.
6
Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.病例报告：携带有 TP53 和 RB1 突变的 EGFR 突变型肺腺癌对 TKI 治疗产生耐药性。
Ann Palliat Med. 2021 Dec;10(12):12886-12893. doi: 10.21037/apm-21-2016.
7
Transformation from adenocarcinoma to squamous cell carcinoma associated with long-term administration of EGFR-TKIs.与长期使用表皮生长因子受体酪氨酸激酶抑制剂相关的腺癌向鳞状细胞癌的转变。
Mol Clin Oncol. 2020 Dec;13(6):82. doi: 10.3892/mco.2020.2152. Epub 2020 Oct 9.
8
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.基于皮升液滴数字聚合酶链反应的游离血浆DNA分析，以评估肺腺癌中对酪氨酸激酶抑制剂产生耐药性的表皮生长因子受体突变
Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14.
9
Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma.表皮生长因子受体（EGFR）突变型肺腺癌的耐药机制及治疗进展
Oncol Lett. 2022 Sep 26;24(5):408. doi: 10.3892/ol.2022.13528. eCollection 2022 Nov.
10
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗的临床结果以及外显子19和21上存在EGFR突变的肺腺癌患者的基因异质性
Chin J Cancer. 2016 Mar 21;35:30. doi: 10.1186/s40880-016-0086-2.
本文引用的文献
1
Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment: A Case report.表皮生长因子受体19号外显子缺失突变的晚期肺腺癌在表皮生长因子受体酪氨酸激酶抑制剂治疗后转化为鳞状细胞癌：一例报告
World J Clin Cases. 2024 Jul 16;12(20):4405-4411. doi: 10.12998/wjcc.v12.i20.4405.
2
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
3
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。
J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.
4
Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.一种双靶点 METxMET 抗体药物偶联物，REGN5093-M114 的临床前研究，克服了 EGFR 突变 NSCLC 中 MET 驱动的获得性对 EGFR TKI 的耐药性。
Clin Cancer Res. 2023 Jan 4;29(1):221-232. doi: 10.1158/1078-0432.CCR-22-2180.
5
Small molecule inhibitors targeting the cancers.靶向癌症的小分子抑制剂。
MedComm (2020). 2022 Oct 13;3(4):e181. doi: 10.1002/mco2.181. eCollection 2022 Dec.
6
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.针对 EGFR 酪氨酸激酶抑制剂耐药的 EGFR 突变型非小细胞肺癌患者的治疗策略和结局：关注新型疗法。
Lung Cancer. 2022 Aug;170:41-51. doi: 10.1016/j.lungcan.2022.05.011. Epub 2022 May 21.
7
Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.非小细胞肺癌的治疗进展：聚焦于靶向治疗和免疫治疗的临床开发
MedComm (2020). 2021 Dec 14;2(4):692-729. doi: 10.1002/mco2.105. eCollection 2021 Dec.
8
Molecular Mechanism of EGFR-TKI Resistance in -Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.EGFR基因变异的非小细胞肺癌中EGFR-TKI耐药的分子机制：在生物学诊断和监测中的应用
Cancers (Basel). 2021 Sep 30;13(19):4926. doi: 10.3390/cancers13194926.
9
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).三代 EGFR-TKI 耐药的机制及处理策略在晚期非小细胞肺癌中的应用（综述）。
Int J Oncol. 2021 Nov;59(5). doi: 10.3892/ijo.2021.5270. Epub 2021 Sep 24.
10
Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.在大型基于人群的队列中，第一代和第二代 EGFR 抑制剂在晚期 EGFR 突变型 NSCLC 中的疗效差异。
Clin Lung Cancer. 2019 Sep;20(5):e576-e583. doi: 10.1016/j.cllc.2019.05.003. Epub 2019 May 11.
Zotero 插件